Gonadorelin (GnRH) Half-Life: 2–10 Minutes
Gonadotropin-releasing hormone decapeptide · Pulsatile: stimulates LH/FSH · Continuous: paradoxical suppression · FDA NDA 017866 (Factrel)
✓ Human PK Study FDA Approved (NDA 017866) Factrel discontinuedQuick Reference
| Parameter | Value | Notes |
|---|---|---|
| Plasma half-life (IV) | ~2–10 minutes | Rapid endopeptidase degradation[1] |
| Effective t½ (SC estimate) | ~30–60 minutes | Slower depot absorption; estimated |
| Endogenous pulse frequency | Every 60–120 min | Hypothalamic arcuate nucleus[2] |
| Molecular weight | 1,182.3 Da | Decapeptide (10 amino acids) |
| Routes | IV, SC | IV for diagnostic; SC off-label for TRT adjunct |
| FDA approval | NDA 017866 (Factrel) | Diagnostic use; voluntarily discontinued |
| Pulsatile effect | ↑ LH + FSH | Gonadotroph activation[2] |
| Continuous effect | ↓ LH + FSH (paradoxical) | GnRHR downregulation[2] |
| Data Quality | ✓ Human PK Study — Half-life established in human IV pharmacokinetic studies | |
The Most Important Pharmacology Concept: Pulsatile vs Continuous
Gonadorelin's ultrashort half-life is not a limitation — it is the biological prerequisite for its mechanism of action. The pituitary gonadotroph cells respond to the pattern of GnRH exposure, not merely the total dose. This distinction is one of the most clinically significant frequency-dependent effects in endocrinology.[2]
In 1980, Ernest Knobil demonstrated this principle definitively in hypothalamus-lesioned rhesus monkeys. Animals receiving pulsatile GnRH at 60-minute intervals maintained normal gonadotropin levels and gonadal function. The same total dose delivered as a continuous infusion suppressed LH and FSH to castrate levels.[2] These findings were subsequently confirmed in humans.
This is not merely an academic distinction. It is the pharmacological foundation for two opposite clinical applications: pulsatile gonadorelin to restore HPG axis function (e.g., hypogonadotropic hypogonadism), and continuous long-acting GnRH agonists (leuprolide, goserelin) to suppress gonadal function (prostate cancer, endometriosis, precocious puberty).
Why the 2–10 Minute Half-Life Is Functionally Essential
Endogenous GnRH is secreted by the arcuate nucleus of the hypothalamus in discrete pulses lasting approximately 2–5 minutes, occurring every 60–120 minutes under normal conditions.[1] The ultrashort half-life ensures that each pulse clears within minutes, allowing the pituitary GnRH receptor (GnRHR) to resensitize before the next pulse arrives.
If GnRH had a longer half-life — like its synthetic agonist analogues — it would maintain continuous receptor occupancy and cause the paradoxical suppression described above. The 2–10 minute t½ is therefore a precision mechanism, not a pharmacokinetic inconvenience.
Routes of Administration and Half-Life by Route
| Route | Half-Life | Use Case | Notes |
|---|---|---|---|
| Intravenous (IV bolus) | ~2–10 min[1] | Diagnostic pituitary testing (Factrel) | Rapid endopeptidase degradation |
| Subcutaneous (SC) | ~30–60 min (estimated) | TRT adjunct protocol (off-label) | Slower absorption extends effective t½ |
| Intranasal | Variable (low bioavailability) | Not established for gonadorelin | Used for buserelin/nafarelin analogues |
| Pulsatile SC pump | Functional t½ set by pump interval | Hypogonadotropic hypogonadism | Used in specialized fertility treatment |
Clearance Timeline (IV, t½ = 5 min midpoint)
Using a conservative midpoint of 5 minutes for IV administration. Gonadorelin clears from plasma within 30–50 minutes of a single IV dose.
| Half-Lives Elapsed | Approximate Time (IV) | % Remaining (theoretical) |
|---|---|---|
| 1 t½ | ~5 minutes | 50% |
| 2 t½ | ~10 minutes | 25% |
| 3 t½ | ~15 minutes | 12.5% |
| 4 t½ | ~20 minutes | 6.25% |
| 5 t½ | ~25 minutes | <3.1% (effectively cleared) |
Mechanism of Action
Gonadorelin is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂) that binds the GnRH receptor (GnRHR), a Gq/11-coupled G-protein-coupled receptor (GPCR) on anterior pituitary gonadotroph cells.
Upon pulsatile GnRH binding:[3]
- GnRHR couples to Gq/11 → activates phospholipase C (PLC)
- PLC generates IP₃ and DAG → intracellular Ca²⁺ release
- Ca²⁺ surge triggers exocytosis of pre-formed LH and FSH granules
- Downstream: LH → Leydig cell testosterone synthesis; FSH → Sertoli cell/follicle support
With continuous GnRH exposure, GnRHR is phosphorylated by GRK kinases and undergoes β-arrestin-mediated internalization, reducing surface receptor density (downregulation) and uncoupling the residual surface receptors from their G-protein cascade (desensitization). This abolishes the LH/FSH response.[2]
Time Your Gonadorelin Protocol Precisely
Halflife Labs tracks injection timing and clearance curves for ultra-short peptides. Log gonadorelin, peptides, and TRT compounds in one place.
Download Halflife LabsGnRH and GnRH Analogue Comparison
| Compound | Half-Life | Effect with Continuous Use | Clinical Use |
|---|---|---|---|
| Gonadorelin (GnRH) | ~2–10 min (IV) | Suppresses LH/FSH (if continuous) | Diagnostic; pulsatile HPG activation |
| Leuprolide (Lupron) | ~3 hours SC | Suppresses LH/FSH (intended) | Prostate cancer, endometriosis, precocious puberty |
| Buserelin | ~1–2 hours SC | Suppresses LH/FSH (intended) | Endometriosis, prostate cancer |
| Cetrorelix (GnRH antagonist) | ~62 hours SC | Immediate LH/FSH suppression | IVF protocols; no flare effect |
Related Compounds in TRT Context
| Compound | Relationship to Gonadorelin | Half-Life |
|---|---|---|
| Testosterone Enanthate | Exogenous androgen that suppresses HPG axis; gonadorelin used to counteract | ~4.5 days |
| HGH (somatropin) | Separate GH axis; occasionally co-administered in TRT protocols | ~3–4 h (SC) |
| IGF-1 (mecasermin) | Downstream mediator of GH; not directly related to HPG axis | ~5.8 h (SC) |
FDA Approval and Regulatory Status
Gonadorelin was approved by the FDA under NDA 017866 as Factrel (gonadorelin hydrochloride, 100 mcg/vial) for diagnostic evaluation of pituitary function. Specifically, Factrel was used to differentiate pituitary from hypothalamic causes of hypogonadotropic hypogonadism: a functional pituitary responds to IV GnRH with an LH surge; a non-functional pituitary does not.
Factrel was voluntarily withdrawn from the U.S. market by Wyeth Pharmaceuticals (formerly Ayerst Laboratories) for commercial — not safety — reasons. The molecule remains pharmacologically active and the NDA is on record with the FDA. Compounded gonadorelin preparations remain available through FDA-registered compounding pharmacies under prescription.
Frequently Asked Questions
What is the half-life of gonadorelin?
Gonadorelin has a plasma half-life of approximately 2–10 minutes after intravenous administration, due to rapid degradation by plasma and tissue endopeptidases.[1] After subcutaneous injection, the effective half-life is estimated at 30–60 minutes due to slower absorption from the depot. The ultrashort IV half-life reflects the biological requirement for pulsatile receptor activation.
Why does continuous gonadorelin suppress LH instead of stimulating it?
Continuous GnRH exposure causes GnRH receptor (GnRHR) internalization and downregulation on pituitary gonadotrophs, uncoupling the receptor from its downstream signaling cascade. The result is paradoxical LH and FSH suppression — the same effect exploited therapeutically by long-acting GnRH agonists for prostate cancer. Knobil (1980) demonstrated this definitively in primates.[2]
Is gonadorelin FDA-approved?
Yes. Gonadorelin was FDA-approved under NDA 017866 (Factrel) for diagnostic pituitary function testing. Factrel was voluntarily discontinued from the U.S. market for commercial reasons, not for safety or efficacy concerns. Compounded gonadorelin remains available under prescription from licensed compounding pharmacies.
What is gonadorelin used for in TRT protocols?
Off-label, gonadorelin is used pulsatile to preserve hypothalamic-pituitary-gonadal axis activity during testosterone replacement therapy. Exogenous testosterone suppresses endogenous LH and FSH via negative feedback, causing testicular atrophy. Pulsatile gonadorelin administration aims to maintain gonadotroph stimulation and preserve testicular size and spermatogenesis.
How does gonadorelin differ from leuprolide and other GnRH agonists?
Gonadorelin is structurally identical to native GnRH with a 2–10 min IV half-life. Long-acting GnRH agonists (leuprolide, buserelin, goserelin) have amino acid substitutions that resist enzymatic degradation, extending half-lives to hours–days. Continuous administration of these agonists causes sustained GnRHR desensitization and LH/FSH suppression — the basis for their use in prostate cancer and endometriosis. Gonadorelin's short half-life allows pulsatile stimulation when properly dosed.
What was the Knobil experiment and why does it matter?
In 1980, Ernest Knobil demonstrated in hypothalamus-lesioned rhesus monkeys that pulsatile GnRH (every 60 minutes) restored normal LH, FSH, and gonadal function, while continuous GnRH infusion at the same total dose caused gonadal suppression equivalent to castration.[2] This established that GnRH pulse frequency — not dose alone — determines the pituitary response, and is the mechanistic foundation for both pulsatile gonadorelin therapy and continuous GnRH agonist suppression.
How is gonadorelin metabolized?
Gonadorelin is degraded by plasma and tissue endopeptidases, primarily at the Tyr5-Gly6 and Pro9-Gly10-NH2 peptide bonds, producing biologically inactive fragments that are cleared renally. This rapid proteolytic catabolism explains the 2–10 minute plasma half-life after IV administration.[3]
What is the difference between gonadorelin and kisspeptin for HPG axis activation?
Gonadorelin acts directly at GnRH receptors on pituitary gonadotrophs to stimulate LH/FSH release. Kisspeptin acts upstream at KISS1R receptors on hypothalamic GnRH neurons to drive endogenous GnRH pulsatility. Gonadorelin bypasses the hypothalamus entirely; kisspeptin requires intact hypothalamic GnRH neurons to have effect. Both can restore LH secretion, through different points in the HPG cascade.
Halflife Labs — Peptide & Hormone Half-Life Tracker
Log gonadorelin, testosterone, peptides, and GLP-1s. Visualize clearance curves from injection time. Understand when each compound is active versus cleared.
Get the App (iOS)References
- Handelsman DJ, Swerdloff RS. Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr Rev. 1986;7(1):95–105. PMID: 3009899
- Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53–88. PMID: 6775465
- Roth JC, Kelch RP, Kaplan SL, Grumbach MM. FSH and LH response to luteinizing hormone-releasing factor in prepubertal and pubertal children, adult males and patients with hypogonadotropic and hypergonadotropic hypogonadism. J Clin Endocrinol Metab. 1972;35(6):926–930. PMID: 3259025
- Factrel (gonadorelin hydrochloride) [prescribing information]. Ayerst Laboratories. NDA 017866. U.S. Food and Drug Administration.
- Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631–633. PMID: 100883
- Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391–405. PMID: 8198390